Cures for HIV and blurred vision and using cosmic rays to monitor nuclear waste drums are on our list of recent promising university spinouts.
CasInvent Pharma’s approach is aimed at three forms of cancer rather than just one, with leukaemia, lymphoma and solid tumours all in its sights.
Non-recyclable plastics making asphalt more sustainable and a vaccine to save the honeybee are just two of 10 inventions that caught our eye.
About half of all vaccines are wasted due to challenges surrounding cold chain logistics, so EnsiliTech aims to remove the need for cold storage.
Spinouts working on ketamine-based therapeutics, regenerative medicines for dogs and better sleep are among those that caught our eye this month.
These are the spinouts that caught our eye over the past month. Here's why they should be on your radar, too.
Launched just a year ago to build on work at Weill Cornell Medicine and New York-Presbyterian Hospital, Cleerly has now closed an oversubscribed series C round.
Cambridge Enterprise has put cash into CardiaTec Biosciences in a pre-seed round that marks the inaugural deal for Laidlaw Scholars Ventures.
UT Southwestern Medical Center spinout ReCode Therapeutics has now raised a total of $200m in its series B round from investors including Osage University Partners.
Osage University Partners has added MicroTransponder to a small but mightly portfolio of medical device companies.
Ascenion and Goethe University Frankfurt are among the initiators of Carma Fund I, which will help start up and fund early life science projects.
Chalmers spinout Elypta is working on a metabolism-based liquid biopsy for early cancer detection that it hopes will catch any type of the disease.
Orphan CNS therapy developer Minoryx Therapeutics closed a $54.8m series C and MIT's The Engine co-led a $10.5m seed round for Foundation Alloy.
Corporate investors are backing a host of elder-care startups, from those seeking Parkinson's cures to apps aiding mental wellbeing.
A Japan-based university spinout is exploring a sound and touch treatment for dementia.
The cancer drug developer popped after an upsized offering, allowing Alexandria Venture Investments to exit and showing the IPO market is still breathing in the US.
The UK health insurer says it is a good time to launch a fund as the froth has come out of valuations and "sensible" money can go in.